Dear Colleagues and Friends,

As Presidents of both ASPIC and ASEICA, it is a pleasure to invite you to participate at the «II ASPIC-ASEICA International Meeting – Current Trends in Precision Medicine in Cancer» that will take place at 14-15 October, 2021. Given the current Covid-19 situation, this meeting will be done as an online event.

The ASPIC (Portuguese Association for Cancer Research – Associação Portuguesa de Investigação em Cancro; www.aspic.pt) and the ASEICA (Spanish Association for Cancer Research – Asociación Española de Investigación sobre el Cáncer; www.aseica.es) are both members of the European Association for Cancer Research (EACR) and, due to common research interests and geographical proximity, decided to establish a strong network of interactions that include, among other activities, the organization of common international scientific meetings and workshops.


Our main purpose is to disseminate and promote the work developed in both countries and create communication channels and collaboration opportunities among cancer researchers in Portugal and Spain. In addition, we place emphasis on fostering essential connections among basic, clinical and translational cancer researchers

As a first step towards that direction, ASEICA and ASPIC already co-organized an Immuno-Oncology meeting in 2019, that occurred in Salamanca, that attracted leading researchers working on this topic in Spain, Portugal and other European countries. The organization of this second ASPIC-ASEICA meeting is an additional step towards the consolidation of this connection between the two associations. In this new activity, we expect to attract the participation of scientists working on Precision Medicine in Cancer. The meeting will have 14 invited speakers plus eight talks selected from abstracts sent by attendees.

We invite you then to join us for the II ASPIC-ASEICA International (Virtual) Meeting. We are sure that you will enjoy it!

Joana Paredes (ASPIC President) & Luis Paz-Ares (ASEICA President)

Scientific & Organizing Commitee

Joana Paredes (ASPIC)
Júlio Oliveira (ASPIC)
Carmen Jerónimo (ASPIC)
Bruno Costa (ASPIC) 
Luisa Melo (ASPIC)

Luis Paz-Ares (ASEICA)
María S. Soengas (ASEICA)
Xosé Bustelo (ASEICA)

Abstracts Evaluation Committee

Ana Preto (ASPIC)
Bruno Costa-Silva (ASPIC)
Célia Gomes (ASPIC)
Fátima Baltazar (ASPIC)
Sílvia Socorro (ASPIC)

Juan Rodriguez Vita (ASEICA)
Miguel Sanmamed (ASEICA)
Mónica Alvarez (ASEICA)
Patricia González Santamaría (ASEICA)
Toni Celià (ASEICA)

Scientific Programme

Europe/Lisbon ( GMT)

14 October, 2021

9:00h – 9:15h

Official Opening

Luis Costa, ASPIC Past President & Xosé Bustelo, ASEICA Past President

9:15h – 10:00h

Opening Lecture

Chair: Bruno Silva-Santos (IMM, Lisbon, Portugal)

Emergent challenges and opportunities in melanoma treatment

Maria S. Soengas (CNIO, Madrid, Spain)

SESSION 1. Target-based cancer therapies

Chair: Bruno Costa (ICVS, Braga, Portugal)

10:00h – 10:30h

Targeted therapy for primary brain tumors

Michael Weller (University of Zurich, Switzerland)

10:30h – 10:45h

Short Talk 1 – Cracking the ErbB2 sugar code in gastric cancer – a bitter sweet functional target

Henrique O. Duarte (i3S, Porto, Portugal)

10:45h – 11:15h


11:15h – 11:45h

Challenges and opportunities for a MYC inhibitor in cancer treatment

Laura Soucek (VHIO, Barcelona, Spain)

11:45h – 12.00h

Short Talk 2 – FGFR inhibition overcomes resistance to EGFR-targeted therapy in epithelial-like cutaneous carcinoma

Purificación Muñoz (IDIBELL, Barcelona, Spain)

12:00h – 12:30h

Patient-derived tumor models for personalized therapeutics in urological cancers

Gabri van der Pluijm (LUMC, Leiden, The Netherlands)

12:30h – 14:00h


SESSION 2. Molecular Cancer Biomarkers

Chair : José Carlos Machado (i3S, Porto, Portugal)

14:00h – 14:30h

Susceptibility Genes for Pancreatic Cancer

Nuria Malats (CNIO, Madrid, Spain)

14:30h – 14:45h

Short Talk 3 – Mitochondrial DNA variants oncogenesis and cancer treatment effectiveness

Aurora Gomez-Duran (CSIC, Madrid, Spain)

14:45h – 15:15h

DNA promoter methylation of homologous recombination genes: a predictive biomarker for the responsiveness to PARP inhibitor treatment in testicular germ cell tumors

Carmen Jerónimo (IPO-Porto & ICBAS-UP, Portugal)

15:15h – 15.30h

Short Talk 4 – Deciphering the impact of cancer cell´s secretome and its derived-peptides on breast cancer brain metastasis

Rita Carvalho (i3S, Porto, Portugal)

15:30h – 16:00h

RANKL-RANK in hormone-dependent breast cancer

Sandra Casimiro (IMM, Lisbon, Portugal)

16:00h – 18:00h

Speed Selected Talks

Chairs : Ana Preto  (CBMA, U.Minho, Braga, Portugal)

Toni Celià-Terrassa  (IMIM, PRBB, Barcelona, Spain)

15 October, 2021

SESSION 3. Novel Cancer Screening Methods

Chair : Sérgio Dias (IMM, Lisbon, Portugal)

9:30h – 10:00h

Uromonitor for the surveillance of non-muscle-invasive bladder cancer patients

Paula Soares (i3S, Porto, Portugal)

10:00h – 10:15h

Short Talk 5 – Inflammatory response of bladder fibroblasts induced by Bacillus Calmette-Guérin-Immunotherapy for non-muscle invasive bladder cancer

Víctor G. Martínez (CIEMAT, Madrid, Spain)

10:15h – 10:45h

Extracellular vesicles in liquid biopsies from cancer patients

EACR SPEAKER – An Hendrix (Ghent University, Ghent, Belgium)

10:45h – 11:15h


11:15h – 11.30h

Short Talk 6 – Mapping the biodistribution of endogenously produced pancreatic cancer exosomes

Bárbara Adem (i3S, Porto, Portugal)

11:30h – 12:00h

Zebrafish avatars as a fast screening platform for cancer therapy

Rita Fior (Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, Portugal)

12:00h – 13:30h


SESSION 4. Novel Targets for Cancer Therapy

Chair : Júlio Oliveira (IPO-Porto, Portugal)

13:30h – 14:00h

Strategies for moving CAR-T cells for solid tumors into the clinic

Sònia Guedan (IDIBAPS, Barcelona, Spain)

14:00h – 14:15h

Short Talk 7 – Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy

Ana Luísa Correia (FMI, Basel, Switzerland)

14:15h – 14:45h

IL-7R signaling as a therapeutic target in acute lymphoblastic leukemia?

João Barata (IMM, Lisbon, Portugal)

14:45h – 15.00h

Short Talk 8 – Combination of poly(I:C)+resiquimod free or loaded in polymeric nanocapsules reprograms tumor associated macrophages in solid tumors

Fernando Torres Andón (CIMUS, Santiago de Compostela, Spain)

15:00h – 15:30h

Antitumour drugs of Marine Origin

José María Fernández Sousa-Faro (CEO Pharma Mar, Spain)

15:30h – 16:00h


16:00h – 16:45h


Chair: Leonor David (Ipatimup & FMUP, Porto, Portugal)

New concepts in precision oncology for breast cancer

Aleix Prat (Medical Oncology, Hospital Clínic de Barcelona, Spain)

16:45h – 17:15h


Joana Paredes, ASPIC President, & Luis Paz-Ares, ASEICA President